These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38912869)
21. Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81. Liang BB; Wang YH; Huang JJ; Lin S; Mao GC; Zhou ZJ; Yan WJ; Shan CY; Wu HZ; Etcheverry A; He YL; Liu FF; Kang HF; Yin AA; Zhang SQ CNS Neurosci Ther; 2024 Apr; 30(4):e14465. PubMed ID: 37830163 [TBL] [Abstract][Full Text] [Related]
22. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461 [TBL] [Abstract][Full Text] [Related]
23. Predictive value of MGMT promoter methylation on the survival of TMZ treated Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600 [TBL] [Abstract][Full Text] [Related]
26. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Wick W; Dettmer S; Berberich A; Kessler T; Karapanagiotou-Schenkel I; Wick A; Winkler F; Pfaff E; Brors B; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Eisenmenger A; von Deimling A; Jones DTW; Pfister SM; Sahm F; Platten M Neuro Oncol; 2019 Jan; 21(1):95-105. PubMed ID: 30277538 [TBL] [Abstract][Full Text] [Related]
27. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244 [TBL] [Abstract][Full Text] [Related]
28. Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. Brawanski KR; Sprung S; Freyschlag CF; Hoeftberger R; Ströbel T; Haybaeck J; Thomé C; Manzl C; Birkl-Toeglhofer AM Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047153 [TBL] [Abstract][Full Text] [Related]
29. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716 [TBL] [Abstract][Full Text] [Related]
30. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343 [TBL] [Abstract][Full Text] [Related]
31. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844 [TBL] [Abstract][Full Text] [Related]
32. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344 [TBL] [Abstract][Full Text] [Related]
33. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Omuro A; Brandes AA; Carpentier AF; Idbaih A; Reardon DA; Cloughesy T; Sumrall A; Baehring J; van den Bent M; Bähr O; Lombardi G; Mulholland P; Tabatabai G; Lassen U; Sepulveda JM; Khasraw M; Vauleon E; Muragaki Y; Di Giacomo AM; Butowski N; Roth P; Qian X; Fu AZ; Liu Y; Potter V; Chalamandaris AG; Tatsuoka K; Lim M; Weller M Neuro Oncol; 2023 Jan; 25(1):123-134. PubMed ID: 35419607 [TBL] [Abstract][Full Text] [Related]
34. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610 [TBL] [Abstract][Full Text] [Related]
35. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. Parkinson JF; Wheeler HR; Clarkson A; McKenzie CA; Biggs MT; Little NS; Cook RJ; Messina M; Robinson BG; McDonald KL J Neurooncol; 2008 Mar; 87(1):71-8. PubMed ID: 18004504 [TBL] [Abstract][Full Text] [Related]
37. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma. Lee A; Malakhov N; Sheth N; Wang A; Han P; Schreiber D Clin Neurol Neurosurg; 2018 Jul; 170():127-131. PubMed ID: 29777945 [TBL] [Abstract][Full Text] [Related]
38. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280 [TBL] [Abstract][Full Text] [Related]
39. Glioblastoma Recurrence and the Role of O Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983 [TBL] [Abstract][Full Text] [Related]
40. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma. Gonzalez-Aponte MF; Damato AR; Trebucq LL; Simon T; Cárdenas-García SP; Cho K; Patti GJ; Golombek DA; Chiesa JJ; Rubin JB; Herzog ED J Neurooncol; 2024 Feb; 166(3):419-430. PubMed ID: 38277015 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]